Nakatani Kaname, Furuta Koh
Rinsho Byori. 2016 May;64(4):392-393.
To date, liquid biopsies have generated much interest as they involve minimally invasive blood tests, pro- vide an ongoing picture of a patient's cancer, and offer valuable insight into the best treatment. Liquid biop- sies detect circulating tumor cells (CTCs), fragments of tumor DNA and exosomes that are shed into the blood from the primary tumor and from metastatic sites. Liquid biopsies offer what tissue biopsies cannot due to risks to the patients and costs. Liquid biopsies allow the monitoring of genomic changes in tumors for the diagnosis of early and recurrent cancer and drug effects. In the future, instead of extensive imaging and invasive tissue biopsies, liquid biopsies could be used to guide cancer treatment decisions and even screen for tumors that are not vet visible on imaging.
迄今为止，液体活检引起了广泛关注，因为它们涉及微创血液检测，能提供患者癌症的动态情况，并为最佳治疗提供有价值的见解。液体活检可检测循环肿瘤细胞（CTC）、肿瘤DNA片段和从原发性肿瘤及转移部位脱落至血液中的外泌体。由于对患者存在风险和成本问题，液体活检具有组织活检所不具备的优势。液体活检能够监测肿瘤中的基因组变化，用于早期和复发性癌症的诊断以及药物疗效评估。未来，液体活检可用于指导癌症治疗决策，甚至筛查影像学上尚未显现的肿瘤，而无需进行广泛的影像学检查和侵入性组织活检。
